Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy) methyl-2-nitroimidazole, a new18F-labeled 2-nitroimidazole analog: Clinical article

Journal of Neurosurgery

Volumn 113, Issue 2, 2010, Pages 358-368

  Shibahara, Ichiyo ^a   Kumabe, Toshihiro ^a   Kanamori, Masayuki ^a   Saito, Ryuta ^a   Sonoda, Yukihiko ^a   Watanabe, Mika ^a   Iwata, Ren ^b   Higano, Shuichi ^a   Takanami, Kentaro ^a   Takai, Yoshihiro ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

FRP 170; Glioma; Hypoxia; Hypoxia inducible factor 1 ; Positron emission tomography; Radioresistance

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; FRP 170; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHIONINE C 11; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BIOPSY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRANIOTOMY; FEMALE; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; HYPOXEMIA; IMMUNOREACTIVITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOSENSITIVITY; UPREGULATION;

ADULT; AGED; ASTROCYTOMA; BIOPSY; BRAIN NEOPLASMS; CARBON ISOTOPES; CELL DIVISION; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; HYPOXIA, BRAIN; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; NITROIMIDAZOLES; OLIGODENDROGLIOMA; POSITRON-EMISSION TOMOGRAPHY; PROTONS; RADIOPHARMACEUTICALS;

EID: 77955596323     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.10.JNS09510     Document Type: Article

References (43)

1. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 90:2232-2242, 2004
2. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rössler K, Prodinger A, et al: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165-171, 2001 (Pubitemid 32623053)
3. Bracken CP, Fedele AO, Linke S, Balrak W, Lisy K, Whitelaw ML, et al: Cell-specific regulation of hypoxia-inducible factor (HIF)-1α and HIF-2α stabilization and transactivation in a graded oxygen environment. J Biol Chem 281:22575-22585, 2006
4. Brizel DM, Dodge RK, Clough RW, Dewhirst MW: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53:113-117, 1999
5. Brown JM: Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys 49:319-326, 2001
6. Brown JM, Workman P: Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82:171-190, 1980
7. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE: Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 46:229-237, 1998
8. Chapman JD, Franko AJ, Sharplin J: A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 43:546-550, 1981
9. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47:410-418, 2006
10. Evans SM, Hahn SM, Magarelli DP, Koch CJ: Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 24:467-472, 2001
11. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al: Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10: 8177-8184, 2004 (Pubitemid 40053376)
12. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2:38-47, 2002
13. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF: Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274:9038-9044, 1999
14. 18F]FRP-170 by on-column hydrolysis. Appl Radiat Isot 62:705-710, 2005
15. 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum 37:599-605, 1986
16. 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 21:101-107, 2007
17. 18F-FRP170. J Nucl Med 43:109-116, 2002
18. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al: Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11- methionine. J Nucl Med 39:778-785, 1998
19. 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29:1176-1182, 2008
20. Kayama T, Yoshimoto T, Fujimoto S, Sakurai Y: Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 74:55-59, 1991
21. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Label Comp Radiopharmaceuticals 42:3-16, 1999
22. Lange T, Dydak U, Roberts TPL, Rowley HA, Bjeljac M, Boesiger P: Pitfalls in lactate measurements at 3T. AJNR Am J Neuroradiol 27:895-901, 2006
23. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al: Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 70:2-13, 2008
24. 18f-fluoromisonidazole. Semin Nucl Med 37: 451-461, 2007
25. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y: Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 12:4747-4754, 2006
26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
27. Martin GV, Caldwell JH, Graham MM, Grierson JR, Kroll K, Cowan MJ, et al: Noninvasive detection of hypoxic myocardium using fluorine-18- fluoromisonidazole and positron emission tomography. J Nucl Med 33:2202-2208, 1992
28. Murayama C, Suzuki A, Sato C, Tanabe Y, Miyata Y, Shoji T, et al: Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration. Int J Radiat Oncol Biol Phys 22: 557-560, 1992
29. Murayama C, Suzuki A, Suzuki T, Miyata Y, Sakaguchi M, Tanabe Y, et al: Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl) ethoxy]methyl-2- nitroimidazole (RP-170). Int J Radiat Oncol Biol Phys 17: 575-581, 1989
30. Nunn A, Linder K, Strauss HW: Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265-280, 1995
31. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 40:1072-1079, 1999
32. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA: Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 17:985-991, 1989
33. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z: Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 122:301-308, 1990
34. Sasai K, Shibamoto Y, Takahashi M, Abe M, Wang J, Zhou L, et al: A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170. Jpn J Cancer Res 80:1113-1118, 1989
35. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8 (4 Suppl):S62-S67, 2002
36. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14:2623-2630, 2008
37. 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 50:36-44, 2009
38. Takai Y, Kaneta T, Hakamatsuka T, Nemoto K, Ogawa Y, Yamada S, et al: [18F]FRP-170: a novel hypoxia marker for PET: animal data analysis, and evaluation in normal volunteers and initial clinical experience. Int J Radiat Oncol Biol Phys 63 (Suppl 1):S465-S466, 2005
39. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, et al: Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 29:191-197, 2002
40. 18F] FENI), a potential agent for imaging hypoxic tissues by PET. J Label Comp Radiopharmaceuticals 43:785-793, 2000
41. Yamasaki F, Takaba J, Ohtaki M, Abe N, Kajiwara Y, Saito T, et al: Detection and differentiation of lactate and lipids by single-voxel proton MR spectroscopy. Neurosurg Rev 28: 267-277, 2005
42. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al: Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194: 795-800, 1995
43. Yasuda H, Nakayama K, Watanabe M, Suzuki S, Fuji H, Okinaga S, et al: Nitroglycerin treatment may enhance chemo-sensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 12:6748-6757, 2006